York-based Abingdon Health signs a strategic partnership agreement with Senzo Health
Under the terms of the partnership Abingdon Health will support Senzo by providing contract development and manufacturing services to Senzo and its partners to enable them to develop and manufacture new rapid tests using Senzo’s ALF platform.
In a statement, Abingdon said: “Senzo is a leading innovator in the rapid diagnostics testing market, with its revolutionary lateral flow technology delivering the same accuracy as laboratory-based PCR with results available within 10 minutes, at a fraction of the cost.
Advertisement
Hide AdAdvertisement
Hide Ad"Senzo Health’s technology is initially being applied to the development of a Covid-19 antigen assay, a broader respiratory panel, and other infectious disease tests. However, there are a wide range of applications across clinical, animal health, food, plant pathogen and environmental testing that would benefit from strengths of Senzo’s platform technology.”
Jeremy Stackawitz, CEO of Senzo Health, commented: “This new partnership, with such an established, innovative, and trusted group as Abingdon, is a terrific opportunity for Senzo as we seek to expand the tests being developed and brought to market on our game-changing ALF platform. Collaborating with Abingdon creates a valuable synergy for customers looking to bring innovative, high-performance lateral flow products to market, and we’re extremely eager to get to work on the first assays.”
Chris Yates, CEO of Abingdon Health, commented: “We are really excited to be working with Senzo and supporting them in leveraging their cutting-edge lateral flow platform technology across multiple applications.